Literature DB >> 23188029

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

Lara K Misegades1, Kathleen Winter, Kathleen Harriman, John Talarico, Nancy E Messonnier, Thomas A Clark, Stacey W Martin.   

Abstract

CONTEXT: In 2010, California experienced its largest pertussis epidemic in more than 60 years; a substantial burden of disease was noted in the 7- to 10-year-old age group despite high diphtheria, tetanus, and acellular pertussis vaccine (DTaP) coverage, indicating the possibility of waning protection.
OBJECTIVE: To evaluate the association between pertussis and receipt of 5 DTaP doses by time since fifth DTaP dose. DESIGN, SETTING, AND PARTICIPANTS: Case-control evaluation conducted in 15 California counties. Cases (n = 682) were all suspected, probable, and confirmed pertussis cases among children aged 4 to 10 years reported from January through December 14, 2010; controls (n = 2016) were children in the same age group who received care from the clinicians reporting the cases. Three controls were selected per case. Vaccination histories were obtained from medical records and immunization registries. MAIN OUTCOME MEASURES: Primary outcomes were (1) odds ratios (ORs) for the association between pertussis and receipt of the 5-dose DTaP series and (2) ORs for the association between pertussis and time since completion (<12, 12-23, 24-35, 36-47, 48-59, or ≥60 months) of the 5-dose DTaP series. Logistic regression was used to calculate ORs, accounting for clustering by county and clinician, and vaccine effectiveness (VE) was estimated as (1 - OR) × 100%.
RESULTS: Among cases and controls, 53 (7.8%) and 19 (0.9%) had not received any pertussis-containing vaccines, respectively. Compared with controls, children with pertussis had a lower odds of having received all 5 doses of DTaP (OR, 0.11; 95% CI, 0.06-0.21 [estimated VE, 88.7%; 95% CI, 79.4%-93.8%]). When children were categorized by time since completion of the DTaP series, using an unvaccinated reference group, children with pertussis compared with controls were less likely to have received their fifth dose within the prior 12 months (19 [2.8%] vs 354 [17.6%], respectively; OR, 0.02; 95% CI, 0.01-0.04 [estimated VE, 98.1%; 95% CI, 96.1%-99.1%]). This association was evident with longer time since vaccination, with ORs increasing with time since the fifth dose. At 60 months or longer (n = 231 cases [33.9%] and n = 288 controls [14.3%]), the OR was 0.29 (95% CI, 0.15-0.54 [estimated VE, 71.2%; 95% CI, 45.8%-84.8%]). Accordingly, the estimated VE declined each year after receipt of the fifth dose of DTaP.
CONCLUSION: Among children in 15 California counties, children with pertussis, compared with controls, had lower odds of having received the 5-dose DTaP series; as time since last DTaP dose increased, the odds increased, which is consistent with a progressive decrease in estimated vaccine effectiveness each year after the final dose of pertussis vaccine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188029     DOI: 10.1001/jama.2012.14939

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  73 in total

Review 1.  Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptake.

Authors:  Annika M Hofstetter; Philip LaRussa; Susan L Rosenthal
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

Review 2.  What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Authors:  Shelly Bolotin; Eric T Harvill; Natasha S Crowcroft
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

3.  Unraveling the challenges of pertussis.

Authors:  Kathryn M Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-31       Impact factor: 11.205

4.  A longitudinal analysis of the effect of nonmedical exemption law and vaccine uptake on vaccine-targeted disease rates.

Authors:  Y Tony Yang; Vicky Debold
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

Review 5.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

6.  Pertussis and the Minnesota State Fair: Demonstrating a Novel Setting for Efficiently Conducting Seroepidemiologic Studies.

Authors:  Erinn Sanstead; Nicole E Basta; Karen Martin; Victor Cruz; Kristen Ehresmann; Shalini Kulasingam
Journal:  J Community Health       Date:  2018-10

7.  Perinatal management of fetal supraventricular tachycardia complicated by maternal pertussis.

Authors:  Stephanie Dejong; Bahram Salmanian; Alireza A Shamshirsaz; Rodrigo Ruano
Journal:  BMJ Case Rep       Date:  2015-07-07

Review 8.  Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.

Authors:  T Roice Fulton; Varun K Phadke; Walter A Orenstein; Alan R Hinman; Wayne D Johnson; Saad B Omer
Journal:  Clin Infect Dis       Date:  2016-02-07       Impact factor: 9.079

Review 9.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Bordetella adenylate cyclase toxin is a unique ligand of the integrin complement receptor 3.

Authors:  Radim Osicka; Adriana Osickova; Shakir Hasan; Ladislav Bumba; Jiri Cerny; Peter Sebo
Journal:  Elife       Date:  2015-12-09       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.